Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
KITE-363 comprises autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20 as well as the CD28 and 4-1BB costimulatory domains, which potentially results in killing of tumor cells expressing CD19 and/or CD20 (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7579).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Cyclophosphamide + Fludarabine + KITE-363||Cyclophosphamide Fludarabine KITE-363||0||1|